Rabbit Polyclonal PRSSL1(C-term) Antibody

+ +

•  

   
     Anti-PRSSL1 Antibody (C-term) at 1:4000 dilution + Human spleen lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 30 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     Immunofluorescent analysis of 4% paraformaldehyde-fixed,  0. 1% Triton X-100 permeabilized A549 cells labeling PRSS57 with P34547 at 1/25 dilution,  followed by Dylight® 488-conjugated goat anti-Rabbit IgG secondary antibody at 1/200 dilution (green).  Immunofluorescence image showing cytoplasm staining on A549 cell line. Cytoplasmic actin is detected with Dylight® 554 Phalloidin at 1/500 dilution (red). The nuclear counter stain is DAPI (blue).    

•  

   
     Overlay histogram showing A549 cells stained with P34547(green line).  The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min.  The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (P34547,  1:25 dilution) for 60 min at 37ºC.  The secondary antibody used was Goat-Anti-Rabbit IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed(1583138) at 1/200 dilution for 40 min at 37ºC.  Isotype control antibody (blue line) was rabbit IgG1 (1μg/1x10^6 cells) used under the same conditions.  Acquisition of >10, 000 events was performed.    

PRSSL1 (Protease, Serine-Like 1), also known as PRSS42 or trypsin-like serine protease, is a member of the trypsin family of serine proteases. It is encoded by the *PRSSL1* gene and is predominantly expressed in the liver. PRSSL1 is proteolytically inactive due to critical substitutions in its catalytic triad, distinguishing it from functional trypsins. However, it retains structural homology with active proteases, suggesting potential non-enzymatic roles in cellular processes. Studies link PRSSL1 to cancer progression, particularly hepatocellular carcinoma (HCC), where its overexpression correlates with tumor growth, metastasis, and poor prognosis. It is proposed to interact with tumor microenvironment components, such as extracellular matrix proteins or signaling molecules, though exact mechanisms remain under investigation.

The PRSSL1(C-term) antibody specifically targets the C-terminal region of the PRSSL1 protein. This region may harbor functional domains critical for protein-protein interactions or regulatory motifs influencing its oncogenic activity. The antibody is widely used in immunoblotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF) to detect PRSSL1 expression in tissue samples or cell lines. Its specificity for the C-terminus helps distinguish PRSSL1 from homologous serine proteases, minimizing cross-reactivity. Researchers utilize this tool to explore PRSSL1's role in liver cancer biology, its diagnostic potential as a biomarker, and its interplay with signaling pathways like Wnt/β-catenin or TGF-β. Ongoing studies aim to clarify its pathophysiological relevance and therapeutic targeting opportunities.